Substance Use Disorders Initiative, Massachusetts General Hospital, Boston, Massachusetts, USA.
Department of Pharmacy, Massachusetts General Hospital, Boston, Massachusetts, USA.
Subst Abus. 2021;42(4):506-511. doi: 10.1080/08897077.2021.1915914. Epub 2021 May 4.
Conventional buprenorphine inductions for OUD are clinically useful but require patients to experience mild to moderate opioid withdrawal symptoms to avoid precipitated withdrawal. This may be intolerable/unreasonable for some, which may have precluded successful buprenorphine treatment in the past. Microdosing buprenorphine, allowing for full agonist opioid overlap, has emerged as a clinically useful strategy for those unable to complete conventional buprenorphine induction. However, many questions remain such as preclusions regarding the amount of full agonist opioid overlap, speed of buprenorphine microdose titration, and overcoming implementation barriers in U.S. hospitals. A female between the ages of 30 and 40 with severe OUD admitted to the hospital for IDU-related osteomyelitis wished to begin buprenorphine for OUD. Her hospitalization was subject to premature discharge at any time due to competing interests of potential foreclosure on her home, so buprenorphine needed to be started rapidly for safety and improved outcomes. Due to her significant acute pain requirements managed with full agonist opioids, it was unreasonable to consider conventional buprenorphine induction. Buprenorphine microdose strategy was employed at more rapid titration and previously described in the literature, starting at 1 mg TDD on day 1, 3 mg TDD on day 2, and 8 mg TDD on day 3 with full agonist opioid overlap starting at 1,944 MME tapered down to 473 MME. The patient prematurely left the hospital, at which time buprenorphine 8 mg TDD was held at this dose for days 3-8 while full agonist opioid was tapered from 473 MME to 117 MME. BUP was then further titrated to 8 mg TID. This patient tolerated buprenorphine microdosing well, without any treatment-emergent opioid symptoms or worsening of baseline symptoms. This case demonstrates the success of buprenorphine microdose induction despite very high doses of full agonist opioid overlap and demonstrates the ability to titrate buprenorphine microdoses faster than originally described. Strategies to overcoming implementation barriers are also discussed.
传统的丁丙诺啡诱导治疗阿片类药物使用障碍(OUD)在临床上是有用的,但需要患者经历轻度到中度的阿片类药物戒断症状,以避免出现戒断症状。对于某些人来说,这可能是无法忍受/不合理的,这可能导致过去丁丙诺啡治疗不成功。丁丙诺啡微剂量给药,允许完全激动剂阿片类药物重叠,已成为那些无法完成传统丁丙诺啡诱导的患者的一种临床有用的策略。然而,仍有许多问题悬而未决,例如完全激动剂阿片类药物重叠的量、丁丙诺啡微剂量滴定的速度,以及克服美国医院实施障碍等。一名年龄在 30 至 40 岁之间的女性,因与 IDU 相关的骨髓炎而住院,患有严重的 OUD,希望开始使用丁丙诺啡治疗 OUD。由于她的住房可能被取消赎回权,她的住院随时可能提前出院,因此为了安全和改善预后,需要迅速开始使用丁丙诺啡。由于她需要使用完全激动剂阿片类药物来治疗严重的急性疼痛,因此考虑传统的丁丙诺啡诱导是不合理的。采用了丁丙诺啡微剂量策略,以更快的速度滴定,并且在文献中有过描述,在第 1 天开始时使用 1mgTDD,第 2 天使用 3mgTDD,第 3 天使用 8mgTDD,同时从第 1 天开始使用 1944MME 的完全激动剂阿片类药物重叠,逐渐减少到 473MME。该患者提前离开医院,此时丁丙诺啡 8mgTDD 剂量保持在第 3 天至第 8 天,同时完全激动剂阿片类药物从 473MME 减少到 117MME。然后将 BUP 进一步滴定至 8mgTID。该患者耐受丁丙诺啡微剂量治疗效果良好,没有出现任何治疗引起的阿片类药物症状或基线症状恶化。该病例证明了即使在高剂量完全激动剂阿片类药物重叠的情况下,丁丙诺啡微剂量诱导也能成功,并证明了比最初描述的更快地滴定丁丙诺啡微剂量的能力。还讨论了克服实施障碍的策略。